Intellia Therapeutics, Inc.
NTLA
$9.06
$0.9611.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 57.53M | 52.86M | 45.57M | 57.88M | 43.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.53M | 52.86M | 45.57M | 57.88M | 43.09M |
| Cost of Revenue | 384.79M | 415.01M | 434.91M | 438.33M | 430.44M |
| Gross Profit | -327.26M | -362.15M | -389.34M | -380.45M | -387.35M |
| SG&A Expenses | 151.47M | 149.87M | 151.73M | 153.81M | 150.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 536.26M | 564.88M | 586.64M | 592.14M | 580.79M |
| Operating Income | -478.73M | -512.02M | -541.07M | -534.26M | -537.71M |
| Income Before Tax | -445.81M | -480.19M | -525.91M | -519.02M | -522.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -445.81 | -480.19 | -525.91 | -519.02 | -522.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -445.81M | -480.19M | -525.91M | -519.02M | -522.28M |
| EBIT | -478.73M | -512.02M | -541.07M | -534.26M | -537.71M |
| EBITDA | -466.25M | -501.87M | -530.80M | -523.98M | -527.52M |
| EPS Basic | -4.27 | -4.69 | -5.23 | -5.25 | -5.45 |
| Normalized Basic EPS | -2.66 | -2.89 | -3.09 | -3.07 | -3.21 |
| EPS Diluted | -4.27 | -4.69 | -5.23 | -5.25 | -5.45 |
| Normalized Diluted EPS | -2.66 | -2.89 | -3.09 | -3.07 | -3.21 |
| Average Basic Shares Outstanding | 419.28M | 410.09M | 403.33M | 395.33M | 383.94M |
| Average Diluted Shares Outstanding | 419.28M | 410.09M | 403.33M | 395.33M | 383.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |